Society for Neuroscience - Search

Skip Navigation

  • join logo Join
  • hands shaped like a yellow heart icon Give
  • advocate logo Advocate
  • publish logo Publish
  • Icon with thought bubbles Learn
Shop Sign In
SfN Logo 2025
  • Membership
    • Learn About Membership
      • Individual Member Benefits
      • Institutional Program Member Benefits
      • Sustaining Associate Member Benefits
      • Get Involved at SfN
    • Become a Member
      • Sponsorship Information for New Members
      • Membership Categories & Fees
      • Membership Fees for Developing Countries
      • Renew Individual Membership
    • Member Resources
      • Automatic Renewals
      • Frequently Asked Questions
      • Individual Member Directory
      • Member Obituaries and Memorial Donations
    • Learn About Local Chapters
      • Start or Reactivate a Chapter
      • Resources for Chapters
      • Submit Annual Report
      • Chapter Directory
      • Frequently Asked Questions
  • Meetings
    • Meetings Overview
    • Neuroscience 2025
      • Presenter Resources
      • Itinerary Planner and Mobile App
      • Sessions and Events
      • Registration
      • Housing and Travel
      • Exhibits
      • Advertising and Sponsorship
      • FAQs
    • Global Events
      • SfN Virtual Events
    • Past and Future Annual Meetings
      • Neuroscience 2024
      • Neuroscience 2023
      • Search Past Annual Meeting Abstracts
      • Attendance Statistics
    • Meeting Policies and Guidelines
      • Code of Conduct at SfN Events
      • Growth and Opportunity Strategy
      • Photography & Recording Policy
      • Presenter Guidelines and Policies for SfN Events
    • Meeting Awards
      • Trainee Professional Development Award
      • International Travel Awards
      • FENS Member Awards to SfN Annual Meeting
      • IBRO Member Awards to SfN Annual Meeting
      • JNS Member Awards to SfN Annual Meeting
  • Careers
    • Careers Overview
    • Institutional Program (IP) Directory
    • NeuroJobs Career Center
      • Job Seekers
      • Employers
    • 2025 Graduate School Fair
    • Career Tools and Resources
      • Neuronline
      • Neurobiology of Disease Workshop
      • Responsible Conduct of Research Short Courses
      • Neuroscience Departments and Program Workshop
      • Global Funding Sources
    • Higher Education and Training
      • Core Competencies
      • Neuroscience Training Program Survey
    • Awards
      • Outstanding Career and Research Achievements
      • Early Career
  • Initiatives
    • Initiatives Overview
    • Awards
      • 2025 Award Recipients
      • Awards and Prizes FAQ
      • Trainee Professional Development Award
    • Neuroscience Scholars Program
    • Neuronline
      • Webinars
      • Articles
      • Videos
      • Podcasts
      • Collections
    • Resources to Stay Connected
      • SfN Zoom Backgrounds
    • Community
    • Women and Neuroscience
      • Increasing Women in Neuroscience (IWiN) Courses & Toolkit
      • Celebration of Women in Neuroscience Event
      • Awards
    • Animals in Research
      • Support for Members and Institutions
      • Tools and Resources
      • Resources for Medical Students
    • Public Education Programs
      • Resources for Educators
      • Brain Awareness Video Contest
      • Life of a Neuron Exhibit
  • Advocacy
    • Advocacy Overview
    • Advocacy Response
    • Advocacy Network
      • The NeuroAdvocate Challenge
      • Advocacy Action Center
      • Advocacy Best Practices
      • Advocacy Network News
      • Advocacy Training Seminars
    • US Advocacy Programs
      • Capitol Hill Day
      • Connect with Policymakers
      • Early Career Policy Ambassadors
      • Partner with a Local Chapter
      • Engage the Media
    • Global Advocacy Programs
      • Global Neuroscience Initiatives
      • Global Funding
      • North American Programs
    • Science Funding
      • Advocacy Videos
      • Advocacy Resources
      • US Neuroscience Initiatives
      • Funding Priorities and Processes
    • Policy Positions
      • Statements and Testimony
      • Sign-On Letters
  • Outreach
    • Outreach Overview
    • BrainFacts.org
    • Find a Neuroscientist
    • Brain Awareness Campaign
      • Webinar: The ABC's of BAW
      • How to Get Involved
    • Awards
      • Award for Education in Neuroscience
      • Next Generation Award
      • Chapter of the Year Award
      • Science Educator Award
  • Publications
    • Publications Overview
    • SfN News
    • JNeurosci
    • eNeuro
    • SfN Nexus
    • Neuroscience Quarterly
    • Annual Report
    • History of Neuroscience Autobiographical Chapters
  • About
    • About Overview
    • Mission and Strategic Plan
    • What We Do
      • Annual Report
      • Bylaws
      • Resolutions to the Bylaws
      • Environmental Commitment
      • Strategic Partners
      • History of SfN
    • SfN 50th Anniversary Celebration
    • NIH Public Health Service-Supported Funding Financial Conflict of Interest Policy
    • Volunteer
      • SfN Council
      • SfN Presidents
      • Committees
      • Elections
      • Call for Nominations
    • Professional Conduct
      • SfN Ethics Policy
      • Guidelines for Responsible Conduct Regarding Scientific Communication
      • Code of Conduct at SfN Events
      • Commitment to Scientific Integrity
      • Neuronline Digital Learning Community Guidelines
    • History of Neuroscience
      • Autobiographical Chapters
      • Autobiographical Videos of Prominent Neuroscientists
      • Classic Papers
      • Neuroscience History Resources
      • Robert Doty's Chapter on Neuroscience
    • Careers and Staff
      • Staff List
  1. Search

Filter

  • (2)
  • (1)
  • (3)
  • (6)
  • (8)
  • (1)
  • (574)
  • (3)
  • (2)
  • (8)
Filter
21 - 30 of 892 results
  • Abstract
    TETRAHYDROCANNABINOL INDUCES APOPTOSIS IN CORTICAL NEURONES.
    E. Downer and V. Campbell. * Dept. of Physiology, Trinity College Dublin, Ireland. Δ9-Tetrahydrocannabinol (THC), the principle psychoactive component of marijuana, elicits diverse psychological effects in humans. At a cellular level THC has been shown to have both neurotoxic1 and neuroprotective effects2. The aim of this study was to examine the role of the stress activated protein kinase (SAPK) c-jun N-terminal kinase (JNK) in THC-induced neurotoxicity in cortical neurones. Treatment of cultured cortical neurones with THC (5µM) for 2h resulted in a 49% increase in genomic DNA strand breaks as assessed by TUNEL staining (p<0.01, paired t-test, n=10). Use of a fluorogenic assay has revealed that caspase-3 activity is increased from 13±6 pmol AFC produced/mg/min (mean±SEM) to 24±8 pmol AFC produced/mg/min following treatment of neurones with THC for 2h. Western Blot analysis showed that cell death was preceded by JNK activation (p<0.05, ANOVA, n=6). The specific role of JNK in this system was assessed by do...
    Nov 7, 2002
  • Abstract
    MARIJUANA EFFECTS ON ATTENTION AND rCBF.
    We previously assessed rCBF following smoking of marijuana and placebo as subjects repeatedly performed the same cognitive task. The task provided a stable cognitive baseline but did not allow assessment of direct vs task-related effects of marijuana. The present doubly-blinded study used PET with [O-15]water to measure rCBF in 12 volunteers who smoked marijuana or placebo cigarettes on 2 occasions at least a week apart. On each occasion subjects were imaged after smoking a marijuana (~20 mg THC) or placebo cigarette while performing 3 auditory tasks; a baseline RT task (also presented before smoking), and dichotic listening tasks with attend-right and attend-left ear instructions. As in our previous studies, smoking marijuana resulted in intoxication (self report), increased rCBF in orbital frontal cortex, anterior cingulate, temporal pole, insula, and cerebellum, and reduced rCBF in auditory and visual cortices. These changes occurred in all 3 tasks and appear to be direct effects of marijuana on rCBF. T...
    Nov 14, 2001
  • Summer 2017
  • Abstract
    Effects of oral Δ-9-tetrahydrocannabinol (THC) on reflexive and voluntary saccades in humans.
    The physiological and anatomical underpinnings of the acute cognitive effects of cannbinoids in humans are poorly understood. Here, we investigated acute cerebral effects of THC in 12 healthy human volunteers. Subjects received 10 mg oral Δ-9-THC (Marinol) and were tested with saccadic paradigms during a period of peak subjective intoxication and peak plasma levels of THC two hours after intake. Compared to baseline testing, no change in accuracy of reflexive saccades was found. However, memory-guided saccades showed a significant increase in variable tageting errors (gain variability: 0.24 vs. 0.19, p = 0.02) and a significant increase in erroneous anticipatory saccades during the memory delay (12.0% vs. 4.3%, p = 0.01). Likewise, a significant increase in antisaccade errors was found (13.2% vs 5.8%, p = 0.008). For all types of saccades, changes in latencies were subtle. Saccadic peak velocities were unaffected by THC. We conclude that oral Δ-9-THC mainly acts on prefrontal components of the saccadic sys...
    Nov 11, 2001
  • Abstract
    Neuronal development in zebrafish is altered by brief exposure (5-hr during gastrulation) to cannabidiol (CBD)
    Marijuana is one of the most commonly used illicit recreational drugs and is widely used for medicinal purposes. Cannabidiol (CBD) is the major non-psychoactive ingredient in marijuana, whereas δ9-Tetrahydrocannabinol (δ9-THC) is the main psychoactive i...
    Nov 4, 2018
  • Abstract
    Proteomics of ∆9-tetrahydrocannabinol (THC) impact on cortical development in health and schizophrenia with iPSC-derived cerebral organoids
    The primary psychoactive compound of cannabis, ∆9-tetrahydrocannabinol (THC), causes depression of glutamate signaling and functional changes in the brain as a result of its interaction with cannabinoid receptor type 1 (CB1) receptors. Neuroimaging stud...
    Nov 10, 2021
  • Abstract
    Comparative potencies of cannabidiol (CBD), cannabigerol (CBG) and cannabichromene oil (CBC oil) in the mouse maximal electroshock test
    Cannabidiol (CBD), a biologically active constituent of the cannabis (hemp) plant, has been approved for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. CBD protects against tonic hindl...
    Nov 9, 2021
  • Abstract
    The subjective response to delta-9-tetrahydrocannabinol (THC) is modulated by activation of endogenous opioid systems in rats.
    Several pharmacological effects of delta-9-tetrahydrocannabinol (THC) are reduced or blocked by administration of opioid antagonists and rewarding or aversive properties of THC are modified in mice lacking opioid receptors. In this study, rats learned to discriminate a 3 mg/kg i.p. injection of THC from an injection of vehicle under a two-lever choice procedure with food reinforcement. We then investigated whether the subjective effects of THC could be blocked or reduced by administration of opioid antagonists and whether opioid agonists could mimic or potentiate THC’s subjective effects. The opioid antagonist naloxone (1 mg/kg, i.p.) produced a small decrease in the discriminative effects of the training dose of 3 mg/kg THC and significantly shifted the THC dose-response curve to the right. When the opioid agonist morphine (1-10 mg/kg, i.p.) was substituted for THC, it did not produce THC-like discriminative effects. However, a 1 mg/kg dose of morphine potentiated the discriminative effects of THC, shifti...
    Nov 11, 2003
  • Abstract
    Development of a mouse model to study the effects of adolescent vaping of Δ-9-tetrahydrocannabinol (THC)
    Cannabis is the most frequently used illicit drug in the world with highest consumption occurring in economically developed countries like the United States, especially among adolescents and young adults. Increased legality of cannabis, and therefore av...
    Oct 23, 2019
  • Abstract
    Changes in the homeostatic roles of microglia induced by cannabidiol (CBD) in a translational model of epilepsy
    Epilepsy is a chronic neurological disorder due to abnormal activity in neuronal circuits and characterized by repeated seizures. It affects 1% of people worldwide and considerably impacts the quality of life of both patients and caregivers. There are c...
    Oct 22, 2019
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

Featured

  • SfN Selects Kevin B. Marvel, PhD, as Next Executive Director
  • Read the Neuroscience Quarterly - Fall 2025
  • Renew your SfN Membership Today!
SfN Websites
  • BrainFacts.org logo
  • eNeuro logo
  • JNeurosci logo
  • Neuronline logo
Engage with SfN
  • join Join
  • give Give
  • advocate Advocate
  • publish Publish
Quick Links
  • SfN News
  • For Press
  • Global Events
  • Contact Us
  • Advertise
  • Code of Conduct
  • Jobs at SfN
  • SfN Store
  • Social Media
Follow SfN
  • BlueSky logo
  • Facebook logo
  • Instagram logo
  • LinkedIn logo

  • Threads logo
  • X Logo
  • YouTube logo
SfN logo with "SfN" in a blue box next to Society for Neuroscience in red text and the SfN tag line that reads "Advancing the understanding of the brain and nervous system"
1121 14th Street NW, Suite 1010, Washington, D.C. 20005
(202) 962-4000 | 1-888-985-9246
  • Accessibility Policy
  • Disclaimer
  • Privacy Notice
  • Contact Us

Copyright ©
Society for Neuroscience